cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.60645/bdc-a68l-ozmp
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Severe Asthma Research Program (SARP)

description: 
**<u>Cohort Description</u> **

The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients. 

**<u>Data Being Submitted</u> **


- Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.- Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.- Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.- Derived data includes 43 variables for up to 463 SARP participants in C4R.- Phenotype data includes 113 variables for up to 463 SARP participants in C4R.
DOI: 10.60645/bdc-3616-096y
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Severe Asthma Research Program (SARP)

description: 
**<u>Cohort Description</u> **

The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients. 

**<u>Data Being Submitted</u> **


- Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.- Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.- Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.- Derived data includes 43 variables for up to 463 SARP participants in C4R.- Phenotype data includes 113 variables for up to 463 SARP participants in C4R.
DOI: 10.60645/bdc-423a-n751
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Severe Asthma Research Program (SARP)

description: 
**<u>Cohort Description</u> **

The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients. 

**<u>Data Being Submitted</u> **


- Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.- Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.- Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.- Derived data includes 43 variables for up to 463 SARP participants in C4R.- Phenotype data includes 113 variables for up to 463 SARP participants in C4R.
DOI: 10.60645/bdc-7bvb-6w5t
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Severe Asthma Research Program (SARP)

description: 
**<u>Cohort Description</u> **

The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients. 

**<u>Data Being Submitted</u> **


- Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.- Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.- Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.- Derived data includes 43 variables for up to 463 SARP participants in C4R.- Phenotype data includes 113 variables for up to 463 SARP participants in C4R.
DOI: 10.60645/bdc-k1rm-wq32
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): REasons for Geographic and Racial Differences in Stroke (REGARDS)

description: None
DOI: 10.60645/bdc-zqkw-05ir
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Prevent Pulmonary Fibrosis (PrePF)

description: 
**<u>Cohort Description</u>** 



Prevent Pulmonary Fibrosis (PrePF) has been investigating the clinical, physiologic and genetic phenotypes of interstitial lung disease (ILD) by focusing on families with two or more cases of ILD and individuals with sporadic IPF. It has recruited over 1,200 families with two or more cases of pulmonary fibrosis. These families with pulmonary fibrosis include 2,837 individuals with probable or definite idiopathic interstitial pneumonia (IIP) and 2,404 unaffected FDRs. In addition, PrePF recruited over 10,000 individuals with sporadic idiopathic pulmonary fibrosis (IPF). 

**<u>Data Being Submitted</u>** 


<li><ul>
Wave 1 questionnaire data includes 397 variables for up to 585 PrePF participants in C4R
DOI: 10.60645/bdc-7025-mlw0
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Mediators of Atherosclerosis in South Asians Living in America Study (MASALA)

description: 
The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is a prospective cohort of South Asians that aims to identify risk factors for heart disease in a large, growing Asian American subgroup. MASALA enrolled 906 South Asians in 2010-2013 and then added a new wave of 258 South Asian participants from 2017-2018, for a full cohort size of 1,164. 

<u>**Data Being Submitted ** </u>
- Wave 1 questionnaire data includes 3967 variables for up to 431 MASALA participants in C4R. - Wave 2 questionnaire data includes 448 variables for up to 313 MASALA participants in C4R. - Dried Blood Spot/Serosurvey data includes 7 variables for up to 248 MASALA participants in C4R. - Derived data includes 43 variables for up to 528 MASALA participants in C4R. - Phenotype data includes 113 variables for up to 429 MASALA participants in C4R.
DOI: 10.60645/bdc-ozky-u793
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Atherosclerosis Risk in Communities Study (ARIC)

description: 
<br><u>**Cohort Description**</u> <br>The Atherosclerosis Risk in Communities (ARIC) study began in the mid-1980s with the initial aims being to describe the presence of subclinical atherosclerosis, the progression of atherosclerosis to clinical cardiovascular disease (CVD), and the association of novel risk factors with CVD. ARIC recruited its cohort of men and women aged 45-64 in 1987-89 from four communities (Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; and Washington County, MD). As of 2020, ARIC counts over 6,000 participants.

<u>**Data Submitted** </u><br>

Wave 1 questionnaire data includes 397 variables for up to 5326 ARIC participants in C4R. <br>Wave 2 questionnaire data includes 448 variables for up to 4619 ARIC participants in C4R. <br>Dried Blood Spot/Serosurvey data includes 7 variables for up to 2083 ARIC participants in C4R. <br>Derived data includes 43 variables for up to 5449 ARIC participants in C4R. <br>Phenotype data includes 113 variables for up to 5449 ARIC participants in C4R. <br>
DOI: 10.60645/bdc-39p5-4xl1
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Atherosclerosis Risk in Communities Study (ARIC)

description: 
<br><u>**Cohort Description**</u> <br>The Atherosclerosis Risk in Communities (ARIC) study began in the mid-1980s with the initial aims being to describe the presence of subclinical atherosclerosis, the progression of atherosclerosis to clinical cardiovascular disease (CVD), and the association of novel risk factors with CVD. ARIC recruited its cohort of men and women aged 45-64 in 1987-89 from four communities (Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; and Washington County, MD). As of 2020, ARIC counts over 6,000 participants.

<u>**Data Submitted** </u><br>

Wave 1 questionnaire data includes 397 variables for up to 5326 ARIC participants in C4R. <br>Wave 2 questionnaire data includes 448 variables for up to 4619 ARIC participants in C4R. <br>Dried Blood Spot/Serosurvey data includes 7 variables for up to 2083 ARIC participants in C4R. <br>Derived data includes 43 variables for up to 5449 ARIC participants in C4R. <br>Phenotype data includes 113 variables for up to 5449 ARIC participants in C4R. <br>
DOI: 10.60645/bdc-m408-wod3
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Multi-Ethnic Study of Atherosclerosis (MESA)

description: 
<u>**Cohort Description **</u>

The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (CVD) and the risk factors that predict progression to clinically overt CVD or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. 

Participants of this study are limited to MESA Classic participants. MESA Family and MESA Air Pollution cohorts are excluded from C4R. 

<u>**Data Being Submitted **</u>
- Wave 1 questionnaire data includes 397 variables for up to 3119 MESA participants in C4R. - Wave 2 questionnaire data includes 448 variables for up to 1933 MESA participants in C4R. - Dried Blood Spot/Serosurvey data includes 7 variables for up to 1058 MESA participants in C4R. - Derived data includes 43 variables for up to 3283 MESA participants in C4R. - Phenotype data includes 113 variables for up to 3136 MESA participants in C4R.
DOI: 10.60645/bdc-hj9a-6206
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Multi-Ethnic Study of Atherosclerosis (MESA)

description: 
<u>**Cohort Description **</u>

The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (CVD) and the risk factors that predict progression to clinically overt CVD or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. 

Participants of this study are limited to MESA Classic participants. MESA Family and MESA Air Pollution cohorts are excluded from C4R. 

<u>**Data Being Submitted **</u>
- Wave 1 questionnaire data includes 397 variables for up to 3119 MESA participants in C4R. - Wave 2 questionnaire data includes 448 variables for up to 1933 MESA participants in C4R. - Dried Blood Spot/Serosurvey data includes 7 variables for up to 1058 MESA participants in C4R. - Derived data includes 43 variables for up to 3283 MESA participants in C4R. - Phenotype data includes 113 variables for up to 3136 MESA participants in C4R.
DOI: 10.60645/bdc-c4q1-g98f
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Northern Manhattan Study (NOMAS)

description: 
<u>**Cohort Description**</u> <br>The Northern Manhattan Study (NOMAS) is a study of the population of Washington Heights in Northern Manhattan. The ongoing study, which began in 1990, has enrolled over 4,400 people, some of whom have suffered a stroke or related neurological syndromes. As the cohort aged, the specific aims grew to include not only vascular determinants of stroke but also cognitive decline, mild cognitive impairment (MCI) and dementia. The overall goal of NOMAS is to investigate stroke risk factors in different race-ethnic groups. NOMAS is also committed to developing better stroke prevention programs to improve the health of the community. The Hispanic population in Northern Manhattan is largely Dominican, along with Puerto Rican, Cuban, and Central and South American components.<br>

<u>**Data Being Submitted**</u> 
 - Wave 1 questionnaire data includes 397 variables for up to 887 NOMAS participants in C4R - Wave 2 questionnaire data includes 448 variables for up to 815 NOMAS participants in C4R - Derived data includes 43 variables for up to 995 NOMAS participants in C4R - Phenotype data includes 113 variables for up to 995 NOMAS participants in C4R
DOI: 10.60645/bdc-u1ze-u8ti
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Coronary Artery Risk Development in Young Adults Study (CARDIA)

description: 
<u>**Cohort Description **</u>

The Coronary Artery Risk Development in Young Adults (CARDIA) study is a study examining the development and determinants of clinical and subclinical cardiovascular disease and their risk factors. It began in 1985-6 with a group of 5115 black and white men and women aged 18-30 years. The participants were selected so that there would be approximately the same number of people in subgroups of race, gender, education (high school or less and more than high school), and age (18-24 and 25-30 years) in each of 4 centers: Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), 2010-2011 (Year 25), 2015-2016 (Year 30), and 2021-2022 (Year 35). 

<u>**Data Being Submitted **</u>
- Wave 1 questionnaire data includes 397 variables for up to 2434 CARDIA participants in C4R- Wave 2 questionnaire data includes 448 variables for up to 1901 CARDIA participants in C4R- Dried Blood Spot/Serosurvey data includes 7 variables for up to 1332 CARDIA participants in C4R- Derived data includes 43 variables for up to 2723 CARDIA participants in C4R- Phenotype data includes 113 variables for up to 2723 CARDIA participants in C4R
DOI: 10.60645/bdc-5o18-eb2v
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Coronary Artery Risk Development in Young Adults Study (CARDIA)

description: 
<u>**Cohort Description **</u>

The Coronary Artery Risk Development in Young Adults (CARDIA) study is a study examining the development and determinants of clinical and subclinical cardiovascular disease and their risk factors. It began in 1985-6 with a group of 5115 black and white men and women aged 18-30 years. The participants were selected so that there would be approximately the same number of people in subgroups of race, gender, education (high school or less and more than high school), and age (18-24 and 25-30 years) in each of 4 centers: Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), 2010-2011 (Year 25), 2015-2016 (Year 30), and 2021-2022 (Year 35). 

<u>**Data Being Submitted **</u>
- Wave 1 questionnaire data includes 397 variables for up to 2434 CARDIA participants in C4R- Wave 2 questionnaire data includes 448 variables for up to 1901 CARDIA participants in C4R- Dried Blood Spot/Serosurvey data includes 7 variables for up to 1332 CARDIA participants in C4R- Derived data includes 43 variables for up to 2723 CARDIA participants in C4R- Phenotype data includes 113 variables for up to 2723 CARDIA participants in C4R
DOI: 10.60645/bdc-1yh8-0p64
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Coronary Artery Risk Development in Young Adults Study (CARDIA)

description: 
<u>**Cohort Description **</u>

The Coronary Artery Risk Development in Young Adults (CARDIA) study is a study examining the development and determinants of clinical and subclinical cardiovascular disease and their risk factors. It began in 1985-6 with a group of 5115 black and white men and women aged 18-30 years. The participants were selected so that there would be approximately the same number of people in subgroups of race, gender, education (high school or less and more than high school), and age (18-24 and 25-30 years) in each of 4 centers: Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), 2010-2011 (Year 25), 2015-2016 (Year 30), and 2021-2022 (Year 35). 

<u>**Data Being Submitted **</u>
- Wave 1 questionnaire data includes 397 variables for up to 2434 CARDIA participants in C4R- Wave 2 questionnaire data includes 448 variables for up to 1901 CARDIA participants in C4R- Dried Blood Spot/Serosurvey data includes 7 variables for up to 1332 CARDIA participants in C4R- Derived data includes 43 variables for up to 2723 CARDIA participants in C4R- Phenotype data includes 113 variables for up to 2723 CARDIA participants in C4R
DOI: 10.60645/bdc-q141-f80v
title: Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Coronary Artery Risk Development in Young Adults Study (CARDIA)

description: 
<u>**Cohort Description **</u>

The Coronary Artery Risk Development in Young Adults (CARDIA) study is a study examining the development and determinants of clinical and subclinical cardiovascular disease and their risk factors. It began in 1985-6 with a group of 5115 black and white men and women aged 18-30 years. The participants were selected so that there would be approximately the same number of people in subgroups of race, gender, education (high school or less and more than high school), and age (18-24 and 25-30 years) in each of 4 centers: Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), 2010-2011 (Year 25), 2015-2016 (Year 30), and 2021-2022 (Year 35). 

<u>**Data Being Submitted **</u>
- Wave 1 questionnaire data includes 397 variables for up to 2434 CARDIA participants in C4R- Wave 2 questionnaire data includes 448 variables for up to 1901 CARDIA participants in C4R- Dried Blood Spot/Serosurvey data includes 7 variables for up to 1332 CARDIA participants in C4R- Derived data includes 43 variables for up to 2723 CARDIA participants in C4R- Phenotype data includes 113 variables for up to 2723 CARDIA participants in C4R
DOI: 10.60645/bdc-656l-6605
title: COVID-19: Post-Hospital Thromboprophylaxis A Multicenter, Adaptive, Prospective, Randomized Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients with COVID-19 Following Hospital Discharge (ACTIV-4C)

description: 
This study is an adaptive, prospective, randomized trial designed to compare the effectiveness and safety of antithrombotic therapy with no antithrombotic therapy after hospitalization for 48 hours or longer for COVID-19. For Stage 1 of this study, participants will be randomized to either prophylactic anticoagulation or no anticoagulant therapy for 30 days, and then followed for an additional 60 days after the completion of treatment (total duration of follow-up, approximately 90 days). Biobanking of samples for future biomarker and mechanistic studies will be available for centers able to participate and collect samples from eligible participants. Samples will be collected at the time of enrollment and after the completion of 30 days of therapy.
DOI: 10.60645/bdc-n0cc-3g87
title: A Pilot Trial of Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in HLA Allo-Immunized Patients

description: 
Platelet transfusion can be a life-saving procedure in preventing or treating serious bleeding in patients who have low and/or dysfunctional platelets. Heavily transfused patients frequently develop human leukocyte antigen (HLA) allo-immunization resulting in platelet transfusion refractoriness and a high risk for life-threatening thrombocytopenia. Data suggest complement activation leading to the destruction of platelets bound by HLA allo-antibodies may play a pathophysiologic role in platelet refractoriness. We conducted a pilot trial to investigate the use of eculizumab to treat platelet transfusion refractoriness in allo-immunized patients with severe thrombocytopenia. We hypothesized that when we treated patients having platelet refractoriness with eculizumab, platelet counts would increase to higher numbers after platelet transfusions, decreasing the risk of bleeding complications associated with having a low platelet count. The response of the treatment was assessed by the corrected platelet count increment (CCI) 10 - 60 min and 18 - 24 h post transfusion, and any requirement for subsequent platelet transfusions following eculizumab. Reference 1 (PMID: [32086819](https://pubmed.ncbi.nlm.nih.gov/32086819/)) contains the main results for this trial.
DOI: 10.5281/zenodo.18504726
title: Data for: Long-term biochar amendment promotes microbial resilience and detoxification in phthalate-contaminated soil

description: ITS and S16 data for soil bacteria and fungi under PAEs stress and biochar remediation.
DOI: 10.60645/bdc-3qf9-yz54
title: ApoA-1 and Atherosclerosis in Psoriasis

description: 
Apolipoprotein A-1 is a protein localized to high-density lipoprotein that functions to remove cholesterol from tissues for transport back to the liver. Psoriasis is a systemic inflammatory disease associated with poor high-density lipoprotein function and accelerated non-calcified burden by coronary computed tomographic angiography. 

In this study, 310 psoriasis patients from The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative ([PACI](https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2013-H-0065)) were studied at baseline to determine if levels of circulating apolipoprotein A-1 predict early onset coronary artery disease in inflammatory conditions. Of the 310 participants, 124 were followed for four years to determine if apolipoprotein A-1 predicts non-calcified coronary burden over time. The primary outcome of this study was non-calcified coronary burden by coronary computed tomography angiography. 

To assess non-calcified coronary burden, participants underwent coronary computed tomography angiography using the same scanner (320-detector row Aquilion ONE ViSION, Toshiba, Japan). For ApoA-1 quantification, fasting blood draw was performed the same day as the coronary computed tomography angiography. The 400MHz proton Vantera Clinical Analyzer was used to quantify Plasma apolipoprotein A-1. 

The study determined that low levels of apolipoprotein A-1 are associated with increased coronary artery burden and that this relationship persists over time. The data are available through dbGaP and the dataset includes all variables reported in the manuscript.
DOI: 10.60645/bdc-u57y-061p
title: Multi-Ethnic Study of Atherosclerosis (BioLINCC)

description: 
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. 

Data available for request include phenotypic data previously released on BioLINCC as well as raw images (E.g. Echocardiogram) and raw tracing data files (e.g. Electrocardiogram). These new data are intended to be made available to interested researchers via BioData Catalyst, will include participants irrespective of participation in genetics (i.e. the full MESA cohort), and may be merged with currently posted (to dbGaP) phenotype and molecular datasets (WGS, GWA, RNA Seq, Methylation, Metabolomics, and Proteomics).